Kineta Inc. (KA)
0.57
-0.26 (-31.33%)
At close: Sep 18, 2024, 8:00 PM
0.60
4.33%
After-hours: Sep 18, 2024, 07:13 PM EDT
Company Description
Kineta, Inc., a clinical stage biotechnology company, develops immunotherapies for oncology, neuroscience, and biodefense.
It serves private, government, and industry partners.
The company has strategic partnerships with Pfizer, Genentech, Wellcome, and Samsung Biologics Co., Ltd.
Kineta, Inc. was formerly known as Lecura, Inc.
The company was incorporated in 2007 and is based in Seattle, Washington.
Kineta Inc.
| Country | United States |
| IPO Date | Feb 11, 2016 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 11 |
| CEO | Craig W. Philips |
Contact Details
Address: 219 Terry Ave. N Seattle, Washington United States | |
| Website | https://kinetabio.com |
Stock Details
| Ticker Symbol | KA |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001445283 |
| CUSIP Number | 49461C102 |
| ISIN Number | US49461C1027 |
| Employer ID | 00-0000000 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Keith A. Baker | Chief Financial Officer |
| Craig W. Philips | President & Secretary |
| Dr. Thierry Guillaudeux Ph.D. | Chief Scientific Officer |
| Gary Gentges | Executive Vice President of Corporate Development |
| Pauline Kenny Esq., J.D. | Advisor |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 08, 2025 | 425 | Filing |
| Mar 28, 2025 | 8-K | Current Report |
| Mar 07, 2025 | 8-K | Current Report |
| Mar 06, 2025 | 10-K | Annual Report |
| Feb 10, 2025 | 8-K | Current Report |
| Dec 12, 2024 | 8-K | Current Report |
| Nov 25, 2024 | DEFA14A | Filing |
| Nov 25, 2024 | 8-K | Current Report |
| Nov 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
| Nov 08, 2024 | 8-K | Current Report |